このエントリーをはてなブックマークに追加
ID 30986
JaLCDOI
FullText URL
Author
Ebara, Shin
Katayama, Yoshihisa
Tanimoto, Ryuta
Edamura, Kohei
Nose, Hiroyuki
Manabe, Daisuke
Kobayashi, Tomoko
Kobuke, Makoto
Takemoto, Mitsuhiro
Saika, Takeshi
Abstract

From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treated using iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatment’s effi cacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classifi ed as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of diffi culty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the fi rst month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and eff ective for localized prostate cancer within short-term follow up.

Keywords
localized prostate cancer
brachytherapy
prostate specific antigen
urinary morbidity
Amo Type
Original Article
Published Date
2008-02
Publication Title
Acta Medica Okayama
Volume
volume62
Issue
issue1
Publisher
Okayama University Medical School
Start Page
9
End Page
13
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Sience KeyUT